TTFields Will Lead Oncological Advancements For Aging Populations
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
04 Aug 25
Updated
16 Aug 25
AnalystHighTarget's Fair Value
US$38.00
68.2% undervalued intrinsic discount16 Aug
US$12.07
1Y
-31.0%7D
6.4%